Published online before print January 3, 2008, doi: 10.1161/ATVBAHA.107.150433
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 American Heart Association, Inc.
Integrative Physiology/Experimental Medicine |
VEGFR1 Tyrosine Kinase Signaling Promotes Lymphangiogenesis as Well as Angiogenesis Indirectly via Macrophage Recruitment
From the Division of Genetics (M.M., Y.Z., M.S.), Institute of Medical Science, University of Tokyo, Japan; the Department of Cell Differentiation (M.H., T.S.), The Sakaguchi Laboratory of Developmental Biology, School of Medicine, Keio University, Japan; the Division of Stem Cell Therapy (Y.M., J.O., H.E.), Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Japan; the Center for Vascular Biology (G.-H.F.), Department of Cell Biology, University of Connecticut Health Center, Farmington; and the Department of Molecular Oncology (M.S.), Tokyo Medical and Dental University, Tokyo, Japan.
Correspondence to Dr Masabumi Shibuya, Department of Molecular Oncology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. E-mail shibuya{at}ims.u-tokyo.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Angiogenesis and lymphangiogenesis are complex phenomena that involve the interplay of several growth factors and receptors. Recently, we have demonstrated that in Keratin-14 (K14) promoter-driven Vegf-A transgenic (Tg) mice, not only angiogenesis but also lymphangiogenesis is stimulated. However, the mechanism by which VEGFR1 is involved in lymphangiogenesis remains unclear.
Methods and Results— To examine how important the tyrosine kinase (TK) of VEGFR1 is in lymphangiogenesis in K14 Vegf-A Tg mice, we crossed the K14 Vegf-A Tg mice with VEGFR1-TK–deficient mice to generate double mutant K14 Vegf-A Tg Vegfr1 tk–/– mice. K14 Vegf-A Tg Vegfr1 tk–/– mice exhibit a remarkable decrease in lymphangiogensis as well as angiogenesis in subcutaneous tissues. To address the mechanism underlying the decrease in lymphangiogensis, we investigated the recruitment of monocyte-macrophage-lineage cells into the skin. The recruitment of VEGFR1-expressing macrophages driven by VEGF-A was reduced in K14 Vegf-A Tg Vegfr1 tk–/– mice. Vegf-A Tg mice that received VEGFR1-TK–deficient bone marrow showed a reduction of macrophage recruitment, lymphangiogenesis and angiogenesis compared with those in K14 Vegf-A Tg mice.
Conclusions— VEGFR1 signaling promotes lymphangiogenesis as well as angiogenesis mainly by increasing bone marrow–derived macrophage recruitment.
Vegf-A transgenic (Tg) mice show not only angiogenesis but also lymphangiogenesis. To examine how important the tyrosine kinase (TK) of VEGFR1 in lymphangiogenesis, we crossed them with VEGFR1-TK–deficient mice. Double mutant mice demonstrated a remarkable decrease in lymphangiogenesis. We found that VEGFR1-signaling promotes lymphangiogenesis indirectly via macrophage recruitment.
Key Words: VEGF-A • VEGFR1 • lymphangiogenesis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Vascular endothelial growth factors (VEGFs) are crucial and potent angiogenic factors that function under physiological and pathological conditions.1 The VEGF family members are key mediators of both angiogenesis and lymphangiogenesis. VEGF-A binds to the VEGF receptors VEGFR1 and VEGFR2, the placental growth factor (PlGF) and VEGF-B bind only to VEGFR1, and VEGF-C and VEGF-D bind to VEGFR3.2–5 VEGFRs are structurally similar and have 7 immunoglobulin (Ig)-like domains in their extracellular domain, and a single transmembrane region and a tyrosine kinase (TK) domain in the cytoplasmic domain.6,7 VEGFR1 and VEGFR2 are highly expressed in vascular endothelial cells and function mainly in angiogenesis.2,8 VEGFR2 and VEGFR3 are highly expressed in lymphatic endothelial cells and function in lymphangiogenesis.9 Other research groups as well as ours have recently shown that VEGFR1 is expressed not only in vascular endothelial cells but also in monocytes/macrophages,10,11 and its signaling is involved in the migration of macrophages toward VEGF-A.12,13 VEGFR1-mediated signaling functions as a positive regulator under various pathological conditions such as tumor progression,14,15 collateral vessel growth, and rheumatoid arthritis in murine models mainly attributable to macrophage recruitment.15,16
See accompanying article on page 604
VEGFR2 plays a crucial role in angiogenesis in both the embryonic and postnatal stages. Vegfr2-null mice display an absence of vasculogenesis and failure to develop blood islands and organized blood vessels.17 It has been demonstrated that VEGFR2 is a major mediator of mitogenic, angiogenic, and permeability-enhancing effects of VEGF-A.18 In contrast, Vegfr1-null mice display embryonic lethality attributable to excessive proliferation and disorganization of the endothelial cells.19 However, it is worth noting that VEGFR1 lacking the TK domain was not lethal and did not cause significant developmental defects except for a decrease in the VEGF-A–dependent migration of macrophages.12 Contrary to the role of VEGFR1 as a positive regulator in the postnatal stage, the abovementioned phenomena suggest that VEGFR1 functions as a negative regulator of vascular development by trapping VEGF-A via its ligand-binding domain in the embryonic stage.
In recent years, lymphangiogenesis has been as much under focus as angiogenesis. Unlike angiogenesis, lymphangiogenesis is believed to be mainly mediated by VEGF-C and VEGF-D and their receptor VEGFR3.5 VEGF-C and VEGF-D also bind VEGFR2, and VEGF-C could affect the permeability via VEGFR2 signaling.20,21 Several studies have suggested VEGFR2 system stimulates lymphangiogenesis as well as angiogenesis.22
Lymphatic vessels serve as a key route for drainage of interstitial fluid that accumulates in tissues, because of leakage from blood vessels and lymphocyte circulation.5 Furthermore, newly developed intra- and peritumoral lymphatic vessels have been reported to increase tumor invasion and metastasis in animal models and human patients.23,24 We and others have recently proven that VEGF-A stimulates both angiogenesis and lymphangiogenesis. Chronic transgenic delivery of human VEGF-A to the mouse skin driven by the Keratin 14 (K14) promoter resulted in highly developed blood and lymphatic vessels along with extensive macrophage recruitment.25 VEGF-A promoted lymphangiogenesis in mouse peritumoral lymphatic vessels, lymphatic metastases,10,26 and overexpression of VEGF-A–impregnated pellets in the cornea.27 However, the possible involvement of VEGFR1 in lymphangiogenesis is yet to be clarified.
To determine the role of VEGFR1 in lymphangiogenesis and angiogenesis, we first examined the degree of angiogenesis and lymphangiogenesis that accompanied macrophage infiltration by using K14 Vegf-A transgenic (Tg) mice and Vegfr1 tk–deficient mice.12,25 Next, because VEGF-A is known to recruit VEGFR1-expressing macrophages, we evaluated the effect of blocking the VEGF-A–dependent recruitment of macrophages on both angiogenesis and lymphangiogenesis by using Vegfr1 tk–deficient bone marrow transplantation (BMT). In addition, vascular permeability, which is related to lymph vessel dilation, was examined in Vegfr1 tk–/– mice.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mice
All the experiments using animal models were carried out according to the guidelines set by the Animal Center of the Institute of Medical Science, The University of Tokyo. To obtain Vegfr1 tk–/– mice with the K14 Vegf-A transgene, Balb/c K14 Vegf-A Tg mice were first crossed with Balb/c Vegfr1 tk–/– mice and then the K14 Vegf-A Tg Vegfr1 tk+/– mice were crossed with Balb/c Vegfr1 tk+/– mice. Vegfr1+/LacZ mice were maintained as described previously.19 Vegfr2+/LacZ mice were purchased from The Jackson laboratory (Bar Harbor, Me).17 For the experiments, 8-week-old littermates were used.
Vascular Permeability Assay
The Miles assay of 8-week-old Balb/c mice (Wild-type [Wt] or Vegfr1 tk–/–) was performed as described previously.28 Images were photographed using a digital camera (Canon EOS). Results represent the mean±SD of triplicate experiments. Experiments were performed using 3 different groups.
Bone Marrow Transplantation
To obtain K14 Vegf-A Tg recipient mice (Balb/cxC57BL/6), we crossed Balb/c K14 Vegf-A Tg male mice and C57BL/6 female mice. Newborn F1 pups were conditioned with intrapartum busulfan (Sigma), 2 intraperitoneal injections of 15 mg/kg of diluted dimethyl sulfoxide (DMSO) on day 18 postcoitus (pc) and day 19 pc, and postnatal total body irradiation (TBI) at a dose of 4.0 Gy; a 2 µL volume of the KSL cell suspension (2x103) from the C57BL/6 donor mice was administered via the orbital venous plexus in the pups.29 Peripheral blood was drawn from recipient animals at 8 weeks posttransplantation to analyze the chimerism of donor type HLA class I. The peripheral blood cells of the recipients were stained with fluorescein isothiocyanate (FITC)-conjugated anti H2Kd and PE-conjugated anti H2Kb antibodies. The Analysis was performed on a fluorescence-activated-cell sorter (FACS).
Statistical Analysis
An Unpaired Student t test was used for all analyses. Differences were considered to be statistically significant at P<0.05 and P<0.01.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Vegfr1 tk–/– Mice Display a Decrease in Lymphangiogenesis as Well as Angiogenesis
We first macroscopically observed the ear skin of 8-week-old littermates obtained by mating Vegfr1 tk+/– mice with K14 Vegf-A Tg Vegfr1 tk+/– mice. The redness of the skin was significantly increased in the K14 Vegf-A Tg mice as compared with Wt mice (supplemental Figure IA versus IC, available online at http://atvb.ahajournals.org). Next, we compared the effect of the VEGFR1 tyrosine kinase and observed that the degree of redness was less in Vegfr1 tk–/– mice than in Vegfr1 Wt mice with K14-driven human VEGF-A (supplemental Figure IB versus IA for Wt ear; Supplemental Figure IE versusI C for K14 Vegf-A Tg Vegfr1 tk Wt ear). In addition, the redness of the K14 Vegf-A Tg Vegfr1 tk+/– mice was between that of K14 Vegf-A Tg Vegfr1 tk+/+ and K14 Vegf-A Tg Vegfr1 tk–/– mice (supplemental Figure IC through IE). Next, we examined the ear using whole-mount immunostaining with the blood vessel-specific marker PECAM-1 and lymphatic endothelial specific marker LYVE1. Consistent with the macroscopic observation, the vascular density, length, and joint number in K14 Vegf-A Tg Vegfr1 tk–/– mice were lower than that in K14 Vegf-A Tg Vegfr1 Wt mice (Figure 1B versus 1A, P<0.05; 1D versus 1C, P<0.05; and graph 1M through 1O).
|
As compared with the blood vessels, the lymphatic vessels in Wt mice were larger in diameter and possessed a loose lymphatic network and blunt end structures, characteristic features of the lymphatic system. Lymphatic vessels of K14 Vegf-A Tg Vegfr1 tk+/+ mice were markedly dilated and increased in number. Interestingly, lymphatic vessel density, length, and joint number were significantly lower in K14 Vegf-A Tg Vegfr1 tk–/– mice than in K14 Vegf-A Tg Vegfr1 tk+/+ mice (Figure 1H versus 1G, P<0.05; graph 1P through 1R). Basal levels of lymphatic vessels in Wt and Vegfr1 tk–/– mice without transgene were similar to each other, although blood vessels were slightly lower in Vegfr1 tk–/– mice (Figure 1A to 1R).
VEGFR1 Is Expressed in the Blood Vessels But Not in the Lymphatic Vessels
Lymphangiogenesis was observed to be suppressed in K14 Vegf-A Tg Vegfr1 tk–/– mice. However, it is not clear yet whether this phenomenon was attributable to direct or indirect VEGFR1 signaling. Therefore, we tested VEGFR1 as well as VEGFR2 expression in the vascular and lymphatic vessels by using Vegfr1+/LacZ and Vegfr2+/LacZ heterozygous mice.17,19 The ear skin of 8-week-old Vegfr1 and Vegfr2 heterozygous mice which possess the LacZ gene at each locus was stained by LacZ (Figure 2A and 2F), β-Gal (Figure 2B and 2G), PECAM-1 (Figure 2C and 2H), and LYVE1 (Figure 2D and 2I). VEGFR1 is expressed in the microvascular blood vessels but not in the lymphatic vessels, whereas VEGFR2 is expressed not only in the microvascular blood vessels but also in the lymphatic vessels. These results suggest that VEGFR1 leads to an increase in lymphangiogenesis by the indirect mechanism.
|
VEGF-A-VEGFR1 Signal Significantly Recruits Macrophages to the Ear
We and others previously demonstrated that VEGFR1 is expressed on monocytes/macrophages,10,11,13 and VEGF-A–dependent migration of macrophages is suppressed in Vegfr1 tk–deficient mice.12 In addition, we have recently reported that K14 Vegf-A Tg mice display recruitment of numerous macrophages to the ear.25 Therefore, we examined the local infiltration of monocytes/macrophages in Vegfr1 tk+/+ and Vegfr1 tk–/– mice. The infiltration of F4/80-positive macrophages was a little weaker in Vegfr1 tk–/– mice than in Wt mice even in the absence of the VEGF-A transgene, although the difference was not significant (Figure 3B versus 3A in Wt mice, and graph 3E). The number of F4/80-positive macrophages was significantly lower in K14 Vegf-A Tg Vegfr-1 tk–/– mice than in K14 Vegf-A Tg Vegfr1 tk+/+ mice (Figure 3D versus 3C, and graph 3E, P<0.05). In real-time RT-PCR analysis using whole ear samples, the expression of Il-6 and Mmp-9 mRNA was higher in Vegf-A Tg group than in non-Tg group (supplemental Figure III). Therefore, these macrophages recruited by VEGF-A through VEGFR1 appear to be closely related to inflammation in the skin. These results suggest that macrophages are involved in both angiogenesis and lymphangiogenesis.
|
VEGF-C Is Secreted From Macrophages
To explain how VEGFR1 indirectly stimulates lymphangiogenesis, we hypothesized that VEGF-A–recruited macrophages secrete VEGF-C. Previously, VEGF-C secreted from macrophages was noted to be important in inflammatory neovascularization. First, we measured the VEGF-A protein level in the ear-skin protein lysate. As expected, the transgene-derived human VEGF-A protein was detected only in the Tg mice, and its expression was not influenced by the absence or presence of the Vegfr1 tk gene (supplemental Figure IVA). The endogenous protein level of mouse VEGF-A was reduced in Tg mice as compared with that in non-Tg mice (supplemental Figure IVB) suggesting a negative feedback loop. The total VEGF-A level (human and mouse) in Tg mice was approximately twice that in non-Tg mice. Recently, macrophage-lineage cells were reported to secrete VEGF-C.25,27 Because macrophages are an important source of VEGF-C, we next compared the mRNA levels of Vegf-C in whole ear by real-time RT-PCR. The level of Vegf-C mRNA in the whole ear was significantly higher in mice with Vegf-A transgene than in wild-type mice. Furthermore, the Vegf-C mRNA in the whole ear was higher in K14 Vegf-A Tg- than in K14 Vegf-A Tg-mice without VEGFR1 TK signal (Vegfr1 tk–/– mice) (Figure 3F, P<0.05). These results suggest that secretion of VEGF-C is associated with the infiltrated macrophage.
Decreased Permeability in Vegfr1 tk–/– Mice
Stromal exudates from blood vessels result in increased ear thickness, and this may cause dilation of the lymphatic vessels to retract the tissue edema. Next, we performed the Miles assay for vascular permeability, using Vegfr1 tk–/– mice to confirm the involvement of VEGFR1 signaling in the enhancement of vascular permeability induced by VEGF-A. The permeability in the Miles assay was significantly weaker in Vegfr1 tk–/– mice than in Wt mice (Figure 4, P<0.05). Vascular permeability is thought to be closely associated with VEGFR2. However, these results reveal that VEGFR1 also promotes vascular permeability along with VEGFR2.
|
Transplantation of Vegfr1 tk–/– Bone Marrow Into Vegf-A Tg Mice Decreased Recruitment of Macrophages, and Suppressed Lymphangiogenesis and Angiogenesis
Macrophages can be recruited to the sites of newly formed blood vessels and lymphatic vessels by VEGF-A via interaction with VEGFR1, and the activated macrophages are known to further stimulate angiogenesis through the secretion of cytokines and stromal interactions.27,30 Because VEGFR1 is expressed in both macrophages and endothelial cells,2,4,8 we examined which cell type, macrophages or endothelial cells, plays an important role in lymphangiogenesis via VEGFR1. For this experiment, we carried out a bone marrow transplantation (BMT) of Vegfr1 tk–/– cells in K14 Vegf-A Tg mice. Wt or Vegfr1 tk–/– BM KSL (c-Kit+, ScaI+, Lineage-) hematopoietic stem cells were transplanted into newborn transgenic pups, because the development of angiogenesis and lymphangiogenesis usually precedes adulthood. After 8 weeks from the BMT, we examined the chimerism and peripheral leukocyte count in the transplanted mice (supplemental Figure VA). Because the genetic background of recipient mice is Balb/cxC57BL/6 mixture, they have H2Kd and H2Kb HLA class I haplotype (supplemental Figure VB-c). On the other hand, donor mice are C57BL/6-genetic background, thus, they have only H2Kb HLA class I type (supplemental Figure VB-b). Chimerism in K14 Vegf-A Tg mice that underwent BMT changed completely to the donor-derived C57BL/6-type BM cells (supplemental Figure VB-d). Recovery of the peripheral leukocyte count and BM cell density in the Wt and Vegfr1 tk–/– BM cell transplanted groups was almost identical (supplemental Figure IVC, D–G). However, cell densities of the transplanted groups were slightly lower than those of the nontransplanted control groups (supplemental Figure IV, D–G). This might be a result of the brief interval required for the complete recovery of BM cell density.
Next, we asked whether BMT with Vegfr1 tk–/– cells results in fewer macrophages being recruited to the ear or not. K14 Vegf-A Tg mice with Vegfr1 tk–/– BM clearly showed a suppression of macrophage recruitment to the ear (Figure 5A and 5B, graph I). We measured the vascular and lymphatic area as well as these length and joint numbers. The representative vascular and lymphatic pictures are shown in Figure 5C through 5H. Graphs J and K in Figure 5 illustrate that a decrease in macrophages caused by BMT substantially inhibited both angiogenesis and lymphangiogenesis although vascular endothelial cells and the stromal cells were VEGFR1 TK+/+ (P<0.05 and P<0.01). In addition to vascular and lymphatic areas, those length and joint numbers in Vegf-A Tg mice with Vegfr1 tk–/– BMT were decreased compared with those in Vegf-A Tg mice with Vegfr1 tk+/+ BMT (both parameter were P<0.05, data not shown). These results suggest that macrophages recruited via the VEGFR1 signal play an important role in lymphangiogenesis as well as angiogenesis.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this study, we have shown that the VEGFR1 TK signals play a significant role in the promotion of lymphangiogenesis and angiogenesis in a murine model with the K14-promoter-driven human Vegf-A transgene. The signaling of VEGFR1 is considered to result in increased vascular permeability and VEGF-A–dependent migration of macrophages into the skin. Furthermore, the K14 Vegf-A Tg mice transplanted with Vegfr1 tk–deficient BM cells did not efficiently recruit macrophages and showed a reduction in angiogenesis and lymphangiogenesis. These results suggest that the signaling of VEGFR1 promotes lymphangiogenesis as well as angiogenesis at least partly via macrophage recruitment and vascular leakage.
Our results raise the question of how VEGFR1 is linked to lymphangiogenesis, directly or indirectly. Lymphangiogenesis is thought to be mainly mediated by the VEGF-C/VEGF-D and VEGFR3 systems.5,9 Also, there is some evidence that VEGF-A has lymphangiogenic properties. Several groups have reported that lymphatic endothelial cells as well as vascular endothelial cells express VEGFR2,9 and the activation of VEGFR2 via VEGF-A promotes lymphangiogenesis.22,31,32 However, our observations indicate that lymphangiogenesis and angiogenesis were reduced in K14 Vegf-A Tg Vegfr1 tk–/– mice compared with Vegfr1 tk wild-type mice although VEGFR2 is intact in both strains (supplemental Figure I and Figure 1). Furthermore, VEGFR1 TK deficiency did not show significant effects on the expression of VEGFR2, VEGFR3, or soluble VEGFR1 (by whole ear real-time RT-PCR analysis, data not shown).12 These results imply that VEGFR1 TK signaling plays a role in lymphangiogenesis. We showed that lymphatic endothelial cells do not express VEGFR1 in Vegfr1+/LacZ mice by using β-gal staining (Figure 2); thus, we suggest that lymphangiogenesis in mice lacking the VEGFR1 signal is impaired indirectly rather than via direct signaling from VEGFR1 TK in lymphatic endothelial cells.
It is of interest to elucidate in detail the mechanisms which promote lymphangiogenesis. Several studies have indicated that VEGF-A increases vascular permeability in microvessels by activating VEGFR2 in endothelial cells.33,34 However, interestingly, in the Miles assay, we observed that the vascular permeability in a short period in Vegfr1 tk–/– mice was suppressed as compared with that in Wt mice. Together with the impaired vascular leakage in Plgf–/– mice35 and increased vascular leakage in K14 PlGF Tg mice,36,37 these results strongly suggest that VEGFR1 directly contributes to vascular leakage (Figure 4A and 4B). Hence, we consider that the stromal exudates from the blood vessels dependent on VEGFR1 signaling also facilitate lymphangiogenesis to drain the excessive fluid into lymphatic vessels.
We and others have shown that VEGFR1 is well expressed in monocytes/macrophages at both the mRNA and protein levels11,13 and that VEGFR1 is important for VEGF-A–dependent migration of these cells.10,12 Therefore, it is reasonable that the infiltration of monocytes/macrophages into the skin was less extensive in Vegfr1 tk–deficient Vegf-A Tg mice than wild-type Vegf-A Tg mice (Figure 3A through 3E). Cursiefen et al and Maruyama et al found that the inhibition of macrophage recruitment suppressed both angiogenesis and lymphangiogenesis in mice with suture-induced inflammatory corneal neovascularization (CNV).27,38 Consistent with these findings, we also demonstrated that the Vegfr-1 tk–deficient K14 Vegf-A Tg mice displayed reduced angiogenesis and lymphangiogenesis in parallel with a decrease in the recruitment of VEGFR1-expressing macrophages (Figure 3A through 3E). In addition, it is noteworthy that we observed a decrease in both angiogenesis and lymphangiogenesis in K14 Vegf-A Tg mice after the replacement of VEGFR1-expressing wild-type macrophages with those lacking only VEGFR1 TK signaling.
Recently, Cursiefen et al reported that the recruited macrophages secreted VEGF-C before promoting lymphangiogenesis and angiogenesis.27 In our case, the total amount of VEGF-A including the K14-derived human type and the endogenous mouse type demonstrated no obvious difference between the wild-type and the VEGFR1 signal-deficient condition (supplemental Figure IVA and IVB). The level of Vegf-C mRNA in the whole ear was significantly higher in mice with Vegf-A transgene than in mice without it. Furthermore, the level of Vegf-C mRNA in the whole ear was significantly higher in K14 Vegf-A Tg- than in K14 Vegf-A Tg-mice without VEGFR1 TK signal. These findings also imply that one of the major resources for the VEGF-C secreted into tissues is the recruited macrophages.
The characterization of macrophages infiltrated into Vegf-A Tg mouse skin is an interesting project. Macrophages were recently reported to be divided to 2 types, M1 (inflammatory, potent nitric oxide–producer) and M2 (predomestic, IL12-p40–dependent), however, still these features seem not conclusive yet, and many experiments and discussions are under way to clarify these types. The numbers of macrophages in the skin are significantly increased in Vegf-A Tg condition compared with normal condition, and the total skin tissues in the Tg mice expressed higher levels of interleukin (IL)-6, matrix metalloproteinase (MMP)-9 (supplemental Figure III), and tumor necrosis factor (TNF)
.25 Thus, we suggest that the macrophages recruited into the Vegf-A Tg skin are closely related to inflammation, not to predomestic ones.
These studies indicate the following possibilities for the involvement of VEGFR1 in lymphangiogenesis. First, VEGFR1 contributes to vascular permeability, and stromal exudates from the blood vessels induce lymph vessel dilatation and lymphangiogenesis. Second, VEGF-A recruits BM-derived macrophages in a VEGFR1 signal–dependent manner. Third, monocyte/macrophages recruited in the tissues express VEGF-C, which is the direct activator for VEGFR3. Lymphangiogenesis is thought to occur directly via the VEGF-C/VEGF-D and VEGFR3 systems. However, our observations indicate that the VEGFR1 signals also play an important role in lymphangiogenesis in certain pathological conditions, particularly proinflammatory diseases. The downstream signaling from VEGFR1 toward cell migration is not yet understood. Such a signaling cascade may be an attractive target for the regulation of abnormal lymphangiogenesis.
|
Acknowledgments |
|---|
We thank Dr Janet Rossant (The Hospital for Sick Children, Toronto, Canada) for supplying the flt-1+/– mice and helpful discussion. We also thank Dr M. Ohtsu (Division of Stem Cell Therapy, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo) for technical assistance and helpful discussions, and Dr S. Yamamoto (Division of Genetics, Institute of Medical Science, University of Tokyo) and Dr C. Furuta (Division of Stem Cell Therapy, Center for Experimental Medicine, Institute of Medical Science, University of Tokyo) for technical assistance.
Sources of Funding
This work was supported by Grant-in-Aid for Special Project Research on Cancer-Bioscience 17014020 and for Scientific Research-B 17390110 from the Ministry of Education, Culture, Sports, Science, and Technology in Japan; a grant for the program "Research for the Future" from the Japan Society for Promotion of Science; and the program "Promotion of Fundamental Research in Health Science" from the Organization for Pharmaceutical Safety and Research (OPSR).
Disclosures
None.
|
Footnotes |
|---|
Original received June 26, 2007; final version accepted December 13, 2007.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27–31.[CrossRef][Medline] [Order article via Infotrieve]
2. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660.[CrossRef][Medline] [Order article via Infotrieve]
3. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002; 2: 727–739.[CrossRef][Medline] [Order article via Infotrieve]
4. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001; 26: 25–35.[CrossRef][Medline] [Order article via Infotrieve]
5. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002; 2: 573–583.[CrossRef][Medline] [Order article via Infotrieve]
6. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990; 5: 519–524.[Medline] [Order article via Infotrieve]
7. Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene. 1998; 208: 297–305.[CrossRef][Medline] [Order article via Infotrieve]
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669–676.[CrossRef][Medline] [Order article via Infotrieve]
9. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005; 438: 946–953.[CrossRef][Medline] [Order article via Infotrieve]
10. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996; 87: 3336–3343.
11. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996; 271: 17629–17634.
12. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A. 1998; 95: 9349–9354.
13. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001; 97: 785–791.
14. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 2001; 61: 1207–1213.
15. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002; 8: 831–840.[CrossRef][Medline] [Order article via Infotrieve]
16. Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, Shibuya M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood. 2006; 108: 1849–1856.
17. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995; 376: 62–66.[CrossRef][Medline] [Order article via Infotrieve]
18. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999; 18: 2221–2230.[CrossRef][Medline] [Order article via Infotrieve]
19. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995; 376: 66–70.[CrossRef][Medline] [Order article via Infotrieve]
20. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998; 95: 548–553.
21. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. Embo J. 1997; 16: 3898–3911.[CrossRef][Medline] [Order article via Infotrieve]
22. Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med. 2007; 204: 1431–1440.
23. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001; 7: 192–198.[CrossRef][Medline] [Order article via Infotrieve]
24. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001; 61: 1786–1790.
25. Zheng Y, Murakami M, Takahashi H, Yamauchi M, Kiba A, Yamaguchi S, Yabana N, Alitalo K, Shibuya M. Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol. 2006; 26: 2019–2026.
26. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005; 201: 1089–1099.
27. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D’Amore PA, Dana MR, Wiegand SJ, Streilein JW. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004; 113: 1040–1050.[CrossRef][Medline] [Order article via Infotrieve]
28. Takahashi H, Hattori S, Iwamatsu A, Takizawa H, Shibuya M. A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. J Biol Chem. 2004; 279: 46304–46314.
29. Yoder MC, Cumming JG, Hiatt K, Mukherjee P, Williams DA. A novel method of myeloablation to enhance engraftment of adult bone marrow cells in newborn mice. Biol Blood Marrow Transplant. 1996; 2: 59–67.[Medline] [Order article via Infotrieve]
30. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006; 124: 175–189.[CrossRef][Medline] [Order article via Infotrieve]
31. Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, Brown LF, Bohlen P, Senger DR, Detmar M. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. Faseb J. 2004; 18: 1111–1113.
32. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002; 196: 1497–1506.
33. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol. 2002; 39: 225–237.[CrossRef][Medline] [Order article via Infotrieve]
34. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest. 2004; 113: 885–894.[CrossRef][Medline] [Order article via Infotrieve]
35. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001; 7: 575–583.[CrossRef][Medline] [Order article via Infotrieve]
36. Oura H, Bertoncini J, Velasco P, Brown LF, Carmeliet P, Detmar M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood. 2003; 101: 560–567.
37. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, Failla CM, Zambruno G. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci. 2002; 115: 2559–2567.
38. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, D’Amore PA, Stein-Streilein J, Losordo DW, Streilein JW. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005; 115: 2363–2372.[CrossRef][Medline] [Order article via Infotrieve]
Related Article:
Arterioscler. Thromb. Vasc. Biol. 2008 28: 604-605.
This article has been cited by other articles:
 |
|
 |
|
  A. Anisimov, A. Alitalo, P. Korpisalo, J. Soronen, S. Kaijalainen, V.-M. Leppanen, M. Jeltsch, S. Yla-Herttuala, and K. Alitalo Activated Forms of VEGF-C and VEGF-D Provide Improved Vascular Function in Skeletal Muscle Circ. Res., June 5, 2009; 104(11): 1302 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kubota, K. Takubo, T. Shimizu, H. Ohno, K. Kishi, M. Shibuya, H. Saya, and T. Suda M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis J. Exp. Med., May 11, 2009; 206(5): 1089 - 1102. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||